
Ami Patel, MD
@amibpatelmd
Hematologist π©πΎββοΈ+π©πΎβπ¬@huntsmancancer @uofuhealth Myeloid leukemias/MPNs. #WomenInSTEM #mpnsm #leusm #northwesternalum ππ Views = my own.
ID: 1113246488274952192
03-04-2019 01:07:00
1,1K Tweet
782 Followers
439 Following

WHAT A CONFERENCE! This was the brain child of Adrienne Dorrance and executed to perfection by an army of people including the amazing folks at Sundance Resort. Thank you to all our incredible attendees, speakers, and sponsors. We couldnβt have done this without all of you! #WBC2025


πππPlease join us at the #ASCO25 #PlenarySession today for our groupβs work on #Rusfertide #HepcidinMimetic Phase 3 Results #VERIFY for patients with Polycythemia Vera π£ Andrew Kuykendall MD Naveen Pemmaraju, MD Kristen Pettit et al meetings.asco.org/abstracts-presβ¦ #MPNSM ASCO


3rd Plenary #ASCO25: #VERIFY Ph III, Rufertide (subcutaneous, hepcidin mimetic) vs Placebo in phlebotomy dependent polycythemia vera. - Improved the need of phlebotomy. Hct control: 76.9% vs 32.9% - Improved symptoms/fatigue By: Drs. Andrew Kuykendall MD & Kathy Walsh, MD, MAEd



πππImportant presentation by Ruben A. Mesa, MD for #MPNSM field at #ASCO25 presenting the #SURPASS-ET study : Positive study for #RopegIFN for patients with high-risk randomized ph3 vs Anagrelide for patients intoler/resistant to prior HU in Essential Thrombocytosis | Lucia Masarova, MD ASCO




Naveen Pemmaraju, MD updating at #ASCO25 PVEK (CD123-ADC) in BPDCN - CADENZA study High & durable response in 1L (de novo and PCHM):CR+CRc= 70% PCHM did not impact OS in 1L Half of 1L who received PVEK subsequently got SCT Good response also for R/R patients Manageable safety profile



#EHA2025 #EHA25 | Just arriving at European Hematology Association meeting - already starting with excellent, highly productive, intense discussions for future directions, future endpoints & thinking about novel mechanisms of #DiseaseModification for MPN field | #MPNSM Claire Harrison




Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abbβ¦




